Are the benefits of benzodiazepines for anxiety disorders underestimated and their risks overestimated?

Prashanth Tibrewal, Claudia Haeusler, Milanduth K. Kanigere, Tarun Bastiampillai

    Research output: Contribution to journalComment/debate

    Abstract

    Benzodiazepines have been officially approved for use in the management of
    anxiety disorders since the 1960s. However, they have been gradually
    going out of favour in preference for medications such as quetiapine, an
    atypical antipsychotic. The reason for this shift is due to concerns regarding
    risk of abuse, dependence, tolerance, withdrawal, sedation, cognitive impairment, psychomotor impairment and suicide-related overdose (Hirschtritt et al., 2021).
    Original languageEnglish
    Pages (from-to)1109-1110
    Number of pages2
    JournalAustralian and New Zealand Journal of Psychiatry
    Volume55
    Issue number11
    Early online dateMay 2021
    DOIs
    Publication statusPublished - Nov 2021

    Keywords

    • Benzodiazepine
    • Anxiety Disorders
    • Risk

    Fingerprint

    Dive into the research topics of 'Are the benefits of benzodiazepines for anxiety disorders underestimated and their risks overestimated?'. Together they form a unique fingerprint.

    Cite this